Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | $16.50 | Buy | Lake Street |
7/16/2024 | $9.00 → $12.00 | Hold → Buy | Stifel |
11/28/2023 | $11.00 | Hold | Stifel |
8/4/2023 | $20.00 → $200.00 | Strong Buy → Outperform | Raymond James |
3/21/2023 | $5.50 → $10.00 | Buy → Hold | Jefferies |
3/7/2022 | $28.00 → $14.00 | Outperform | Cowen & Co. |
2/22/2022 | $28.00 → $23.00 | Strong Buy → Outperform | Raymond James |
6-K - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Mizuho raised the price target for Microsoft Corporation (NASDAQ:MSFT) from $450 to $480. Mizuho analyst Gregg Moskowitz maintained an Outperform rating. Microsoft shares gained 0.1% to close at $453.96 on Monday. See how other analysts view this stock. HC Wainwright & Co. boosted the price target for Revolution Medicines, Inc. (NASDAQ:RVMD) from $44 to $56. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Revolution Medicines shares gained 1.9% to close at $46.00 on Monday. See ho
Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights Q3-2024 revenue growth of 64% over Q3-2023.Profound continued to see a wide variety of prostate dise
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services ("CMS") has released its final rule (the "Final Rule") establishing, for the first time, a Category 1 CPT® code for the Transurethral Ult
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2024 Results Conference Call Details: Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI0b43a811a8b6
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50
Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously
Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights Q3-2024 revenue growth of 64% over Q3-2023.Profound continued to see a wide variety of prostate dise
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2024 Results Conference Call Details: Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI0b43a811a8b6
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed base grew from 53 at the end of Q1-2024 to 57 as of the end of Q2-2024;
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp
TORONTO, May 15, 2024 /CNW/ - Profound Medical Corp. (TSX:PRN) (NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all